



Reimbursement in Healthcare

Louise Perrault
Founder & CEO (IMAC)
27 March 2024



INTERNATIONAL
MARKET ACCESS CONSULTING
Making your innovations reach patients



OBJECTIVES:

1

Introduce the process of translating basic research and clinical trial results into tangible societal benefits in the healthcare sector

2

Learn the key steps and requirements for successfully entering the healthcare market with innovative hepatology products

3

What is required for presenting research findings to relevant stakeholders and securing reimbursement for new treatments or technologies


About IMAC

- Boutique firm specialized in Market Access
- Founded in 2006 in Zug, Switzerland
- Established in Canada since 2010
- Global reach: European and North American focus



IMAC supports the product lifecycle

From early planning to post-launch




OVERVIEW

- 1 UK Healthcare Landscape
- 2 Introduction to Drug Reimbursement/
UK Landscape
- 3 Considerations for Commercialisation
- 4 Recommendations/Future Outlook



1 UK Healthcare Landscape

- The UK Healthcare System
- Drug Commissioning



After pandemic and Brexit challenges, the UK pharma industry is expected to experience a positive shift in 2024

The UK has faced three major unexpected events in the past eight years: the Brexit referendum and implementation, a global pandemic, and a major conflict in Eastern Europe



UK's economic outlook is strengthening, and public finances have improved, with a narrowing deficit



The UK's "Life Sci for Growth" budget of £650 million, announced by the Chancellor, includes support for innovation and clinical trials in the sector


The NHS is the dominant force in the UK's healthcare system, which comprises public and private provisions

Dominated by NHS

NHS varies across UK nations but shares key concepts. NHS in England is the largest market

Universal Access (for most)

Everyone in the UK receives emergency and some mental health care, regardless of residency status. Residency may be required for non-emergency services




Public Funding

Primarily funded by taxes, ensuring affordability at the point of service for most treatments

Private sector exists

A growing private healthcare market also exists, funded by patients or insurance.

NHS England is a central body responsible for commissioning most healthcare services in England



The structure of NHS England is evolving

Source: National Assembly for Wales, 2015

Reimbursement policies are vital for patient access, health outcomes, and healthcare affordability and efficiency

Drug reimbursement is a crucial healthcare policy, impacting multiple stakeholders and influencing various aspects of the system

Ensuring
patient access
to essential
medications


Encouraging
the appropriate
use of
medications

Equity and
Fairness


Controlling
healthcare costs

Promoting
innovation in drug
development

2 Introduction to Drug Reimbursement/ UK Landscape




Preparing for reimbursement success is crucial; regulatory approval alone is not sufficient for patient access



Drug reimbursement refers to the process by which the cost of prescription medications is covered or subsidised, either partially or fully, by the National Health Service (NHS) or other healthcare schemes

The reimbursement system aims to ensure that patients have access to essential medications without facing significant financial burden

Regulatory ensures drug safety and efficacy, while reimbursement assesses value for healthcare decisions



MHRA ASSESSMENT

- Assessed by national/EU regulatory bodies
- The regulatory process ensures:



EFFICACY



SAFETY



QUALITY



NICE (HTA) ASSESSMENT

- Evaluated by health technology assessment (HTA) agencies/health insurance systems
- Assesses an intervention's potential benefits and value compared to other available options
- Varies from country to country
- Assessment can include the following :



CLINICAL EFFECTIVENESS



SAFETY

AND




COST-EFFECTIVENESS




BUDGET IMPACT

A robust Pricing and Reimbursement strategy is essential for achieving commercial success




Strategic planning should start early, to ensure alignment with payer requirements



While the NICE appraisal is the main route, there are alternative access pathways for promising interventions with limited data

The UK's drug reimbursement pathway is a multi-step process that determines whether a medication is covered by the NHS



NICE conducts a detailed review of the treatment's clinical and cost-effectiveness based on submitted evidence

NICE appraisal includes a review of:

- Clinical benefits compared to existing treatments (including health-related quality of life, HRQoL)
- Cost-effectiveness (CE) compared to existing treatments considering the price of the product
- Impact on the healthcare budget (medications costing more than £20m/year for the NHS in the first three years)

NICE's assessment process for new treatments includes:

1 Scoping

The scope defines the disease, the patients and the technologies covered by the appraisal and the questions it aims to answer

2 Assessment

Assesses the clinical and cost-effectiveness evidence of the treatment and considers input from various stakeholders (clinicians, patient groups and manufacturers)

3 Appraisal

- An appraisal committee decides whether the new treatment should be funded by the NHS
- Decision-making considers:
 - the strength of clinical evidence
 - patient clinical needs
 - cost-effectiveness
 - the robustness of economic evaluation
 - budget impact (if applicable)

NICE Outcome:

Recommended

Optimised
(restricted patient
populations)

Recommended for use
in the CDF/IMF

Only in research


Not recommended



INTERNATIONAL
MARKET ACCESS CONSULTING
Making your innovations reach patients

Cost-effectiveness evaluation is a key consideration in NICE's decision-making process, with CE thresholds needing to be met for a positive recommendation

NICE evaluates the cost-effectiveness (CE) of new drugs compared to existing treatments to determine which drugs offer the most benefits for their costs




Various types of NICE Technology appraisals are available to help improve access to treatments, each associated with different CE thresholds


Appraisal Type		NICE's CE threshold
Single Technology Appraisals (STA)	One medical technology for a specific indication	£20,000 to £30,000 per QALY (higher if severity modifier applied)
Fast Track Appraisals (FTA)	Quicker assessments for highly promising technologies with a threshold below £10,000 per QALY	£10,000 per QALY
Multiple Technology Appraisals (MTA)	Compare multiple related technologies or different uses of one technology and are more complex and time-consuming than STAs	-
Highly Specialised Technologies (HSTs)	Treatments for rare diseases	£100,000 - £300,000 per QALY (to account for high development costs and limited patient population)

3 Considerations for Commercialisation

- Key Reimbursement Challenges
- Considerations for Combinations Therapies



The reimbursement landscape is evolving, with companies requiring innovative strategies such as value-based pricing and real-world evidence, to ensure timely access to effective treatments



Meeting cost-effectiveness requirements and cross-company pricing negotiations are key challenges for manufacturers launching combination/high-cost therapies

HTA Challenges

Challenging for combination therapies to reach the required 'cost-effectiveness' threshold to obtain a recommendation

Pricing/Commercial agreement challenges

Competition law prohibits companies from negotiating agreements on product prices

Demonstrating the combined and individual value of the products to negotiate prices effectively is challenging

While customised pricing is allowed for combination therapies, meeting the criteria for pricing flexibility can be challenging


Granular prescribing data required for components of the combination for transacting commercial agreements



Potential solutions are being explored with various stakeholders involved

- A negotiation framework to support cross-company dialogue has been developed by the APBI
- Two potential methods to attribute value across components of combination therapies have been proposed
- Potential solutions to resolving implementation hurdles related to combination/indication-specific pricing and the data required to transact commercial agreements are being explored.

4 Recommendations/ Future Outlook



Early strategic planning is recommended for commercialisation success



Early engagement
with regulatory and
reimbursement
bodies



Generating robust
clinical and
economic
evidence



Patient advocacy
and stakeholder
engagement



Pricing and
reimbursement
negotiations



Post-
reimbursement
market access
strategies

QUESTIONS?



imac

imarketaccess.com

CONFIDENTIAL

Due to a lack of long-term data, NICE recommended using IsaPD with the CDF, and a discount was needed to meet NICE's cost-effectiveness threshold

Regulatory

Product: Sarclisa (isatuximab) + Imnovid (pomalidomide) + dexamethasone (**IsaPD**)

Manufacturer: Sanofi

Indication: 3L+ treatment of Multiple Myeloma

EMA approval: 26 March 2020

Pivotal trial: ICARIA-MM (IsaPd vs Pd); Phase 3, multicenter, randomized open-label study



HTA

NICE Final Appraisal Date: 18 November 2020

HTA Indication: Manufacturer positioned the treatment for 4L+ treatment of MM in the UK (aligning with local clinical practice)

HTA Outcome: Recommended for use within the Cancer Drugs Fund with a Managed Access Agreement

Key decision drivers

- Benefits demonstrated in improving disease progression and overall survival compared to Id. However, the long-term benefits were unclear
- Cost-effectiveness estimates were also uncertain and exceeded the NICE threshold, due to limitations in clinical data, leading to the recommendation for use in the Cancer Drugs Fund with further data collection and a managed access agreement

